Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZN-A-1041 Formulation 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | - |
| Sequence 2 | EXPERIMENTAL | - |
| Sequence 3 | EXPERIMENTAL | - |
| Sequence 4 | EXPERIMENTAL | - |
| Sequence 5 | EXPERIMENTAL | - |
| Sequence 6 | EXPERIMENTAL | - |
| Sequence 7 | EXPERIMENTAL | - |
| Sequence 8 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ZN-A-1041 Formulation 1 | DRUG | Participants will receive a single dose of ZN-A-1041 Formulation 1 on each specified treatment. |
| ZN-A-1041 Formulation 2 | DRUG | Participants will receive a single dose of ZN-A-1041 Formulation 2 on each specified treatment. |
| Rabeprazole | DRUG | Participants will receive an oral administration of rabeprazole twice daily (BID) on days 9, 10, 15, and 16 and a single dose on Days 11 and 17. |
Inclusion Criteria: * Body mass index (BMI) within the range of 18 to 32 kg/m2, inclusive * In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, and vital signs, as determined by the investigator, at Screening and Check-in, as app...
ZN-A-1041 Formulation 1 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is currently in Phase 1 clinical development. The completed trial evaluated its pharmacokinetics, specifically how food and a proton pump inhibitor affect its absorption and processing in the body.
ZN-A-1041 Formulation 1 is being developed by Roche Holding AG, traded on the OTC market under the ticker RHHBY. The company is conducting clinical research on this investigational small molecule in healthy volunteers.
ZN-A-1041 Formulation 1 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The single Phase 1 trial has been completed, and the drug is not currently in any active clinical trials.
ZN-A-1041 Formulation 1 has one completed clinical trial, NCT07329972, titled 'A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants.' This Phase 1 study enrolled 24 healthy adults in the United States and was a controlled, randomized trial.
ZN-A-1041 Formulation 1 is a specific formulation of the investigational drug ZN-A-1041. The clinical trial NCT07329972 evaluates this particular formulation in healthy volunteers. No other alternative names for this drug have been disclosed.